Retatrutide
Weight Management · Triple Receptor Agonist · Metabolic
View Product & Pricing →What Is Retatrutide?
Retatrutide (LY3437943) is a once-weekly injectable peptide that simultaneously activates three receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR). This tri-agonist mechanism distinguishes it from earlier GLP-1 mono-agonists and the dual GLP-1/GIP agonist Tirzepatide.
Phase 2 clinical trial data published in 2023 (NEJM) demonstrated significant reductions in body weight over 48 weeks, with the highest dose group achieving a mean weight loss of approximately 24% — among the largest reported for any pharmacological intervention in metabolic research.
How It Works
Retatrutide's tri-receptor mechanism engages complementary pathways: GLP-1 receptor activation reduces appetite and slows gastric emptying; GIP receptor activation modulates insulin secretion and may enhance GLP-1 effects; glucagon receptor activation increases energy expenditure and hepatic fat oxidation. The combined effect appears to produce greater metabolic impact than individual or dual-receptor approaches.
Key Research Findings
Phase 2 Trial Results
A randomised, double-blind Phase 2 trial (Jastreboff et al., NEJM 2023) in adults with obesity demonstrated dose-dependent weight reduction of 17–24% over 48 weeks, significantly exceeding outcomes with GLP-1 monotherapy in comparable trials.
Glucagon Receptor Component
The addition of glucagon receptor agonism is a key differentiator — glucagon increases resting energy expenditure and promotes lipolysis. Preclinical data suggests the glucagon component may reduce hepatic steatosis independent of weight loss alone.
Cardiometabolic Markers
Alongside weight outcomes, Phase 2 data showed improvements in HbA1c, fasting insulin, triglycerides, and blood pressure — consistent with broad metabolic benefit beyond adiposity reduction.
Ongoing Phase 3
Retatrutide is currently progressing through Phase 3 trials (TRIUMPH programme) across populations including obesity, type 2 diabetes, and cardiovascular risk, with results anticipated in 2025–2026.
Research-Grade Retatrutide
Pharmaceutical-grade formulation. Order via WhatsApp or Telegram.
For research purposes only. This page does not constitute medical advice. Consult a qualified healthcare professional before use. Clinician review required where mandated by law.